Sep 8, 2026, 18:44 UTC
Genmab A/S increased its share capital by 28,011 shares due to the exercise of employee warrants, without preemption rights for existing shareholders.
Source:Aug 6, 2026, 18:04 UTC
Genmab announced two new Phase III studies of petosemtamab in colorectal cancer.
Source:Jun 30, 2026, 09:35 UTC
Genmab and AbbVie announced that their drug combination for lymphoma met the primary goal in a late-stage clinical trial.
Source: